Golodirsen - Sarepta Therapeutics

Drug Profile

Golodirsen - Sarepta Therapeutics

Alternative Names: Exon 53 PMO; SRP 4053

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sarepta Therapeutics
  • Class Antisense oligonucleotides; Morpholines
  • Mechanism of Action Dystrophin expression modulators; Genetic transcription inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Duchenne muscular dystrophy

Most Recent Events

  • 22 May 2018 Sarepta Therapeutics plans a phase III extension trial for Duchenne muscular dystrophy in June 2018 (NCT03532542)
  • 12 Mar 2018 Sarepta Therapeutics announces intention to submit NDA to US FDA for Duchenne muscular dystrophy by end of 2018
  • 06 Sep 2017 Interim efficacy data from a phase I/II trial in Duchenne muscular dystrophy released by Sarepta Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top